

Blood-Retinal Barrier

[View the current Blood-Retinal Barrier InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Blood-Retinal_Barrier.html) - Regularly Updated.

Recent Publications on Blood-Retinal Barrier:



- [Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity.](#)
*The retina maintains homeostasis through the blood-retinal barrier (BRB)....*20th November, 2009
Department of Ophthalmology, Seoul National University College of Medicine- Nanotechnology. 2009 Nov 19;20(50):505101. ([DOI Direct Link](#))
- [Atrial Natriuretic Peptide Reduces Vascular Leakage and Choroidal Neovascularization.](#)
*Atrial natriuretic peptide (ANP) is a hormone with diuretic, natriuretic,...*17th November, 2009
From the Angiogenesis Laboratory,* Massachusetts Eye & Ear Infirmary, and- Am J Pathol. 2009 Nov 12. ([DOI Direct Link](#))
- [Cationic amino acid transporter 1-mediated L-arginine transport at the inner blood-retinal barrier.](#)
*The purpose of this study was to identify the transporter mediating...*7th November, 2009
Department of Pharmaceutics, Graduate School of Medicine and- J Neurochem. 2009 Nov;111(3):716-25. Epub 2009 Aug 27. ([DOI Direct Link](#))
- [Involvement of LAT1 and LAT2 in the high- and low-affinity transport of L-leucine in human retinal pigment epithelial cells \(ARPE-19 cells\).](#)
*System L, which is encoded by LAT1 and LAT2, is an amino acid transport...*6th November, 2009
Department of Pharmaceutics, Graduate School of Medicine and- J Pharm Sci. 2009 Nov 4. ([DOI Direct Link](#))
- [Optical coherence tomography of macular thickness after biaxial vs coaxial microincision clear corneal cataract surgery.](#)
*Purpose. To evaluate macular thickness changes after biaxial microincision...*3rd November, 2009
Department of Ophthalmology, Johannes Gutenberg-University, Mainz -- Eur J Ophthalmol. 2009 Nov-Dec;19(6):991-8.
- [A novel non-radioactive method to evaluate vascular barrier breakdown and leakage.](#)
*PURPOSE. To identify a novel sensitive non-radioactive leakage assay that...*31st October, 2009
Retina, Harvard,MEEI, Boston, United States.- Invest Ophthalmol Vis Sci. 2009 Oct 29. ([DOI Direct Link](#))
- [Clusterin inhibits blood-retinal barrier breakdown in diabetic retinopathy.](#)
*PURPOSE. To investigate whether clusterin could attenuates blood-retinal...*31st October, 2009
Ophthalmology, Seoul National University Hospital, Seoul, Korea, Republic- Invest Ophthalmol Vis Sci. 2009 Oct 29. ([DOI Direct Link](#))
- [Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration.](#)
*Autoantibody production is associated with a variety of ocular disorders,...*23rd October, 2009

Dobbs Ocular Immunology Laboratories, Emory Eye Center and Department of- J Autoimmun. 2009 Nov-Dec;33(3-4):247-54. Epub 2009 Oct 27. ([DOI Direct Link](#))

- [IFN \$\gamma\$ Regulates Retinal Pigment Epithelial Fluid Transport.](#)
*The present experiments show that IFN γ receptors are mainly localized...*2nd October, 2009
National Institutes of Health.- Am J Physiol Cell Physiol. 2009 Oct 7. ([DOI Direct Link](#))
- [A role for photoreceptors in retinal oedema and angiogenesis: an additional explanation for laser treatment?](#)
*Purpose To investigate the possible roles of retinal photoreceptors in...*12th September, 2009
[1] Singapore Eye Research Institute, Singapore National Eye Centre,- Eye. 2009 Sep 11. ([DOI Direct Link](#))
- [Inhibition of Vitreoretinal VEGF Elevation and Blood-Retinal Barrier Breakdown in Streptozotocin-Induced Diabetic Rats by Brimonidine.](#)
*Purpose. To determine whether chronic brimonidine (BRI) treatment prevents...*28th August, 2009
Biological Sciences, ALLERGAN, INC., IRVINE, California, United States.- Invest Ophthalmol Vis Sci. 2009 Aug 26. ([DOI Direct Link](#))
- [Imaging of macroaneurysms occurring during retinal vein occlusion and diabetic retinopathy by indocyanine green angiography and high resolution optical coherence tomography.](#)
*BACKGROUND: Macular edema occurring after retinal vein occlusion (RVO) or...*25th August, 2009
Department of Ophthalmology of the Fondation Ophtalmologique Rothschild,- Graefes Arch Clin Exp Ophthalmol. 2009 Aug 25. ([DOI Direct Link](#))
- [Kininogen is decreased in peripheral blood stream but increased in target tissue of autoimmune uveitis.](#)
*Purpose. Equine recurrent uveitis is an incurable disease affecting the...*22nd August, 2009
LMU Munich, Institute of Animal Physiology, Department of Veterinary- Invest Ophthalmol Vis Sci. 2009 Aug 20. ([DOI Direct Link](#))
- [Mechanisms for transcellular diapedesis: probing and pathfinding by 'invadosome-like protrusions'.](#)
*Immune-system functions require that blood leukocytes continuously traffic...*21st August, 2009
Center for Vascular Biology Research, Beth Israel Deaconess Medical- J Cell Sci. 2009 Sep 1;122(Pt 17):3025-35. ([DOI Direct Link](#))
- [Glial cell factors and the outer blood retinal barrier.](#)
*The retinal pigment epithelium is an important barrier to drug transport...*20th August, 2009
Department of Optometry and Visual Science, Henry Wellcome Laboratories- Ophthalmic Physiol Opt. 2009 Sep;29(5):557-64. ([DOI Direct Link](#))

Blood-Retinal Barrier Patents:



- 7078391- [Method of treating edematous retinal disorders](#)
- 7153822- [Compositions and methods for modulating connexin hemichannels](#)
- 7172874- [Diagnostic methods for age related macular degeneration](#)
- 7195774- [Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues](#)
- 7214659- [Reduction of the electrocardiographic QT interval](#)
- 7223744- [Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof](#)
- 7230032- [Calcium blockers to treat proliferative vitreoretinopathy](#)
- 7247702- [Periocular drug delivery for diabetic retinopathy](#)
- 7259180- [Methods and compositions for treatment of macular and retinal disease](#)

- 7297505- [Use of MDCK cell line to predict corneal penetration of drugs](#)
- 7303746- [Methods of treating eye disorders with modified chimeric polypeptides](#)
- 7148199- [Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation](#)
- 7141610- [Compositions and methods for the induction of retinal detachments](#)
- 7141607- [Methods and compositions for treating and inhibiting retinal neovascularization](#)
- 7081482- [Use of .beta.-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina](#)
- 7083802- [Treatment of ocular disease](#)
- 7083803- [Ocular solutions](#)
- 7087237- [Ocular solutions](#)
- 7090864- [Non-invasive gene targeting to ocular cells](#)
- 7091240- [Tubulin binding ligands and corresponding prodrug constructs](#)
- 7097850- [Bioactive agent release coating and controlled humidity method](#)
- 7101577- [Extract of plant Dendrobii caulis and preparing process thereof](#)
- 7115566- [Compounds and method for the prevention and treatment of diabetic retinopathy](#)
- 7125901- [Thiazole derivatives](#)
- 7303747- [Use of VEGF inhibitors for treatment of eye disorders](#)
- 7306799- [Use of VEGF inhibitors for treatment of eye disorders](#)
- 7531525- [P.sup.1-\(2'-deoxycytidine 5'-\)P.sup.4-\(uridine 5'-\)tetraphosphate, tetra-\(alkali metal\) salt, for treating cystic fibrosis](#)
- 7541048- [Coating compositions for bioactive agents](#)
- 7544673- [Coating compositions for bioactive agents](#)
- 7553496- [VEGF-A as an inhibitor of angiogenesis and methods of using same](#)
- 7560257- [Diagnostic methods for age related macular degeneration](#)
- 7576189- [Antibodies to human vascular endothelial growth factor 2 and methods of using the same](#)
- 7585839- [Medical uses of intercellular communication facilitating compounds](#)
- 7585865- [Protein kinase C zeta inhibition to treat vascular permeability](#)
- 7592016- [Methods for preparing and using implantable substance delivery devices](#)
- 7601341- [Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis](#)
- 7524501- [Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies](#)
- 7521049- [Use of VEGF inhibitors for treatment of eye disorders](#)
- 7498417- [Antibodies to vascular endothelial growth factor 2 and methods of using same](#)
- 7341839- [Diagnostic methods for age related macular degeneration](#)
- 7354574- [Treatment of ocular disease](#)
- 7384925- [Functionalized stilbene derivatives as improved vascular targeting agents](#)
- 7393942- [Nucleic acids encoding mutant forms of Fas ligand](#)
- 7419666- [Treatment of ocular disorders](#)
- 7429681- [Combretastatin analogs with tubulin binding activity](#)
- 7442402- [Bioactive agent release coating](#)
- 7442715- [Thiazole derivatives](#)
- 7452680- [MCT1 transporters expressed in blood brain barrier cells](#)
- 7456214- [Chromene-containing compounds with anti-tubulin and vascular targeting activity](#)
- 7601840- [Carboline derivatives useful in the inhibition of angiogenesis](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

